000097220 001__ 97220
000097220 005__ 20230622083309.0
000097220 0247_ $$2doi$$a10.1177/1753466620963021
000097220 0248_ $$2sideral$$a120990
000097220 037__ $$aART-2020-120990
000097220 041__ $$aeng
000097220 100__ $$0(orcid)0000-0001-9096-2294$$aMarín, J.M.$$uUniversidad de Zaragoza
000097220 245__ $$aEfficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
000097220 260__ $$c2020
000097220 5060_ $$aAccess copy available to the general public$$fUnrestricted
000097220 5203_ $$aObjectives: The IMPACT trial has compared the benefit in the reduction of moderate/severe exacerbations of single inhaler triple therapy (SITT) with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus dual therapy with FF/VI (ICS/LABA) and UMEC/VI (LAMA/LABA) in the treatment of patients with chronic obstructive disease (COPD). This study performs a subgroup analysis of the cohort from Spain in the IMPACT study.
Materials and Methods: In IMPACT, a 52-week randomized, double-blind, parallel-group, multicenter study (N = 10, 355), patients ¿40 years of age with COPD and ¿1 moderate/severe exacerbations in the previous year were randomized 2:2:1 to once-daily FF/UMEC/VI 100/62.5/25 µg, FF/VI 100/25 µg or UMEC/VI 62.5/25 µg administered via the Ellipta inhaler. Here, we present a subgroup analysis of the 499 patients from Spain, included in the intent-to-treat (ITT) population in the study. Endpoint assessed included exposure-adjusted rate of moderate and severe exacerbations.
Results: In the Spain cohort, the exposure-adjusted rate of on-treatment moderate/severe COPD exacerbations per year for FF/UMEC/VI was 1.31 versus 1.43 and 1.57 for FF/VI and UMEC/VI, respectively. No new adverse events were identified. The results are consistent with those observed in the overall ITT study population.
Conclusion: In the Spain cohort of the IMPACT study, patients receiving triple therapy with FF/UMEC/VI had a lower exposure-adjusted rate of exacerbations compared with FF/VI and UMEC/VI, similar to the overall population.
000097220 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000097220 590__ $$a4.031$$b2020
000097220 591__ $$aRESPIRATORY SYSTEM$$b22 / 64 = 0.344$$c2020$$dQ2$$eT2
000097220 592__ $$a1.022$$b2020
000097220 593__ $$aPulmonary and Respiratory Medicine$$c2020$$dQ2
000097220 593__ $$aPharmacology (medical)$$c2020$$dQ2
000097220 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000097220 700__ $$aMateos, L.
000097220 700__ $$aRoldán, J.
000097220 700__ $$aEchave-Sustaeta, J.M.
000097220 700__ $$aPascual-Guardia, S.
000097220 700__ $$aPardo, M.V.
000097220 700__ $$aVelasco, B.
000097220 700__ $$aJones, C.E.
000097220 700__ $$aKilbride, S.
000097220 700__ $$aLipson, D.A.
000097220 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000097220 773__ $$g14 (2020), [10 pp]$$pTher. adv. respir. dis.$$tTherapeutic Advances in Respiratory Disease$$x1753-4658
000097220 8564_ $$s204345$$uhttps://zaguan.unizar.es/record/97220/files/texto_completo.pdf$$yVersión publicada
000097220 8564_ $$s29069$$uhttps://zaguan.unizar.es/record/97220/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000097220 909CO $$ooai:zaguan.unizar.es:97220$$particulos$$pdriver
000097220 951__ $$a2023-06-21-14:59:34
000097220 980__ $$aARTICLE